Not specific—commonly refers to “High-affinity immunoglobulin E receptor” (FcεRI) or “MAS-related G protein-coupled receptor X2” (MRGPRX2) when discussing therapeutic targets on mast cells (FcεRI (for the IgE receptor), MRGPRX2 (for the GPCR involved in pseudo-allergic reactions))

Mast cell targets typically refer to cell-surface receptors or key molecular effectors on mast cells that mediate activation, degranulation, and signaling. The major and therapeutically relevant mast cell receptors include the high-affinity IgE receptor (FcεRI), which is central to allergic diseases, and MRGPRX2, a GPCR responsible for pseudo-allergic reactions and host defense pathways. Targeting these receptors with drugs (e.g., antihistamines, mast cell stabilizers, monoclonal antibodies, or selective antagonists) is an active area of clinical research for allergies, inflammation, and immunological disorders. “Mast cell target” is not a specific entity but rather a general category; appropriate canonical identification must specify the exact molecule or receptor (e.g., “high-affinity immunoglobulin E receptor” or “MAS-related G protein-coupled receptor X2”)

Other names

Mast cell IgE receptorFc epsilon RI (FcεRI)MAS-related G protein-coupled receptor X2 (MRGPRX2)Mast cell GPCRMast cell activation receptorOther mast cell surface markers (CD117/KIT, histamine receptors, chemokine receptors, etc.)

FcεRI antagonists: inhibit IgE cross-linking, prevent mast cell activation Mast cell stabilizers: prevent degranulation by stabilizing membrane Antihistamines: block histamine receptor signaling MRGPRX2 antagonists: block pseudo-allergic mast cell activation Anti-IgE antibodies: reduce IgE available for receptor binding